Literature DB >> 20111659

Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women.

Carolyn J Alexander, Edward P Tangchitnob, Norman E Lepor.   

Abstract

The prevalence of polycystic ovary syndrome (PCOS) is estimated to be nearly 10% among reproductive-age women. PCOS may represent the largest underappreciated segment of the female population at risk of cardiovascular disease. Clinicians providing care to women of childbearing age must recognize the presenting clues, including irregular menses, hirsutism, alopecia, hyperandrogenemia, and obesity. The pathophysiology of PCOS is complex, involving the hypothalamus-pituitary-ovarian axis, ovarian theca cell hyperplasia, hyperinsulinemia, and a multitude of other cytokine- and adipocyte-driven factors. Cardiac risk factors associated with PCOS have public health implications and should drive early screening and intervention measures. There are no consensus guidelines regarding screening for cardiovascular disease in patients with PCOS. Fasting lipid profiles and glucose examinations should be performed regularly. Carotid intimal medial thickness examinations should begin at age 30 years, and coronary calcium screening should begin at age 45 years. Treatment of the associated cardiovascular risk factors, including insulin resistance, hypertension, and dyslipidemia, should be incorporated into the routine PCOS patient wellness care program.

Entities:  

Keywords:  Cardiovascular disease; Carotid intimal medial thickness; Coronary calcium screening; Diabetes; Obesity; Polycystic ovary syndrome

Year:  2009        PMID: 20111659      PMCID: PMC2812885     

Source DB:  PubMed          Journal:  Rev Obstet Gynecol        ISSN: 1941-2797


  42 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

Review 2.  Clinical application of C-reactive protein for cardiovascular disease detection and prevention.

Authors:  Paul M Ridker
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

3.  Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease.

Authors:  C Meyer; B P McGrath; H J Teede
Journal:  J Clin Endocrinol Metab       Date:  2005-07-26       Impact factor: 5.958

4.  Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women.

Authors:  A Corbould
Journal:  J Endocrinol       Date:  2007-03       Impact factor: 4.286

5.  Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.

Authors:  Vicken Sepilian; Manubai Nagamani
Journal:  J Clin Endocrinol Metab       Date:  2004-10-13       Impact factor: 5.958

6.  Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone.

Authors:  J Adams; S Franks; D W Polson; H D Mason; N Abdulwahid; M Tucker; D V Morris; J Price; H S Jacobs
Journal:  Lancet       Date:  1985 Dec 21-28       Impact factor: 79.321

7.  Health implications of overweight and obesity in the United States.

Authors:  T B Van Itallie
Journal:  Ann Intern Med       Date:  1985-12       Impact factor: 25.391

8.  Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden.

Authors:  L Lapidus; C Bengtsson; B Larsson; K Pennert; E Rybo; L Sjöström
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-10

9.  Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome.

Authors:  C J Glueck; Ranganath Papanna; Ping Wang; Naila Goldenberg; Luann Sieve-Smith
Journal:  Metabolism       Date:  2003-07       Impact factor: 8.694

10.  Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome.

Authors:  Basak Yildirim; Nuran Sabir; Babur Kaleli
Journal:  Fertil Steril       Date:  2003-06       Impact factor: 7.329

View more
  19 in total

1.  Renal Sympathetic Denervation for Treatment of Hypertension.

Authors:  Eduardo Pimenta; Suzanne Oparil
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-02-01

2.  Aspects of Cardiometabolic Risk in Women with Polycystic Ovary Syndrome.

Authors:  Thomas S Paterakis; Evanthia Diamanti-Kandarakis
Journal:  Curr Obes Rep       Date:  2014-12

3.  Assessing and treating insulin resistance in women with polycystic ovarian syndrome.

Authors:  Michael L Traub
Journal:  World J Diabetes       Date:  2011-03-15

4.  Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes.

Authors:  Berna Dilbaz; Enis Ozkaya; Mehmet Cinar; Evrim Cakir; Serdar Dilbaz
Journal:  Endocrine       Date:  2011-03-10       Impact factor: 3.633

Review 5.  Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis.

Authors:  Patricia Hernandez; Neena Passi; Taher Modarressi; Vivek Kulkarni; Meshal Soni; Fran Burke; Archna Bajaj; Daniel Soffer
Journal:  Curr Atheroscler Rep       Date:  2021-09-13       Impact factor: 5.113

6.  Clinical practice guideline of the Interamerican Society of Cardiology on primary prevention of cardiovascular disease in women.

Authors:  Mildren A Del-Sueldo; María A Mendonça-Rivera; Martha B Sánchez-Zambrano; Judith Zilberman; Ana G Múnera-Echeverri; María Paniagua; Lourdes Campos-Alcántara; Claudia Almonte; Amalia Paix-Gonzales; Claudia V Anchique-Santos; Claudine J Coronel; Gabriela Castillo; María G Parra-Machuca; Ivanna Duro; Paola Varletta; Patricia Delgado; Verónica I Volberg; Adriana C Puente-Barragán; Adriana Rodríguez; Aida Rotta-Rotta; Anabela Fernández; Ana C Izeta-Gutiérrez; Ana E Ancona-Vadillo; Analía Aquieri; Andrea Corrales; Andrea Simeone; Bibiana Rubilar; Carolina Artucio; Carolina Pimentel-Fernández; Celi Marques-Santos; Clara Saldarriaga; Christian Chávez; Cristina Cáceres; Dahiana Ibarrola; Daniela Barranco; Edison Muñoz-Ortiz; Edith D Ruiz-Gastelum; Eduardo Bianco; Elena Murguía; Enrique Soto; Fabiola Rodríguez-Caballero; Fanny Otiniano-Costa; Giovanna Valentino; Iris B Rodríguez-Cermeño; Ivan R Rivera; Jairo A Gándara-Ricardo; Jesús A Velásquez-Penagos; Judith Torales; Karina Scavenius; Karen Dueñas-Criado; Laura García; Laura Roballo; Lucía R Kazelian; Macarena Coussirat-Liendo; María C Costa-Almeida; Mariana Drever; Mariela Lujambio; Marildes L Castro; Maritza Rodríguez-Sifuentes; Mónica Acevedo; Mónica Giambruno; Mónica Ramírez; Nancy Gómez; Narcisa Gutiérrez-Castillo; Onelia Greatty; Paola Harwicz; Patricia Notaro; Rocío Falcón; Rosario López; Sady Montefilpo; Sara Ramírez-Flores; Silvina Verdugo; Soledad Murguía; Sonia Constantini; Thais C Vieira; Virginia Michelis; César M Serra
Journal:  Arch Cardiol Mex       Date:  2022

7.  Correlation between steroid hormonal levels and cardiac function in women during controlled ovarian hyperstimulation.

Authors:  Yiran Li; Xiuhua Sun; Lili Zang; Quan Zhang; Jichun Li; Shuhua Zou
Journal:  Endocrine       Date:  2013-04-11       Impact factor: 3.633

8.  Polycystic Ovary Syndrome and the Forgotten Uterus.

Authors:  Pardis Hosseinzadeh; Maya Barsky; William E Gibbons; Chellakkan S Blesson
Journal:  F S Rev       Date:  2020-12-13

Review 9.  A Narrative Review of Current Understanding of the Pathophysiology of Polycystic Ovary Syndrome: Focus on Plausible Relevance of Vitamin D.

Authors:  Rajeshwari Kalyanaraman; Lubna Pal
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 5.923

10.  Anti-Inflammatory Dietary Combo in Overweight and Obese Women with Polycystic Ovary Syndrome.

Authors:  Amany Alsayed Salama; Ezzat Khamis Amine; Hesham Abd Elfattah Salem; Nesrin Kamal Abd El Fattah
Journal:  N Am J Med Sci       Date:  2015-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.